The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro

References

• Atkins WM. (2005). Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45:291–310
   PubMed Web of Science ®Google Scholar
• Bloomer JC, Clarke SE, Chenery RJ. (1995). Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl]caffeine. Xenobiotica 25:917–27
   PubMed Web of Science ®Google Scholar
• Busby WF, Jr. Ackermann JM, Crespi CL. (1999). Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246–9
   PubMed Web of Science ®Google Scholar
• Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4
   PubMed Web of Science ®Google Scholar
• Easterbrook J, Lu C, Sakai Y, Li AP. (2001). Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141–4
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. (2006). Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug--drug interaction patterns. Xenobiotica 36:219–33
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A, Kirchheiner J. (2007). Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81:270–83
   PubMed Web of Science ®Google Scholar
• Fuhr U, Wolff T, Harder S, et al. (1990). Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos 18:1005–10
   PubMed Web of Science ®Google Scholar
• Hickman D, Wang JP, Wang Y, Unadkat JD. (1998). Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207–15
   PubMed Web of Science ®Google Scholar
• Huang W, Lin YS, McConn DJ, 2nd et al. (2004). Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434–45
   PubMed Web of Science ®Google Scholar
• Kot M, Daniel WA. (2008). The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol 76:543–51
   PubMed Web of Science ®Google Scholar
• Maenpaa J, Hall SD, Ring BJ, et al. (1998). Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137–55
   PubMedGoogle Scholar
• Manolis E, Osman TE, Herold R, et al. (2011). Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth 21:214–21
   PubMed Web of Science ®Google Scholar
• Meunier B, De Visser SP, Shaik S. (2004). Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. Chem Rev 104:3947–80
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kandikere V, Bhyrapuneni G, et al. (2011). Effect of dimethyl sulfoxide on in vitro cytochrome P4501A2 mediated phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 39:2162–4
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Emoto C, Yamazaki H. (2008). Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 9:20–33
   PubMed Web of Science ®Google Scholar
• Obach RS. (1996). The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro--in vivo correlations. Drug Metab Dispos 24:1047–9
   PubMed Web of Science ®Google Scholar
• Ogino H, Ishikawa H. (2001). Enzymes which are stable in the presence of organic solvents. J Biosci Bioeng 91:109–16
   PubMed Web of Science ®Google Scholar
• Otten JN, Hingorani GP, Hartley DP, et al. (2011). An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metab Lett 5:17–24
   PubMedGoogle Scholar
• Patki KC, Von Moltke LL, Greenblatt DJ. (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938–44
   PubMed Web of Science ®Google Scholar
• Rokitta D, Fuhr U. (2011). Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab 11:153–61
   Web of Science ®Google Scholar
• Shaik S, Kumar D, De Visser SP, et al. (2005). Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. Chem Rev 105:2279–328
   PubMed Web of Science ®Google Scholar
• Soars MG, Grime K, Riley RJ. (2006). Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 36:287–99
   PubMed Web of Science ®Google Scholar
• Song WY, Ji HY, Baek NI, et al. (2010). In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes. Arch Pharm Res 33:1985–96
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. (2005). Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859–66
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Lutjohann D, Doroshyenko O, et al. (2009). Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther 86:147–53
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, et al. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–91
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D Klement S, et al. (2012). Effect of Ginkgo biloba special extract EGb 761(R) on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68:553–60
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell PM, Paxton JW. (2002). Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. J Pharm Pharmacol 54:997–1003
   PubMed Web of Science ®Google Scholar